New answer by Medical Oncologist at Yale School of Medicine (January 16, 2019)
In my practice, I try to avoid the strong CYP2D6 inhibitors when I plan to prescribe tamoxifen (e.g. for low risk hormone-receptor positive breast cancer in a young premenopau...